Tyra Biosciences, Inc.
NASDAQ:TYRA
Overview | Financials
Company Name | Tyra Biosciences, Inc. |
Symbol | TYRA |
Currency | USD |
Price | 14 |
Market Cap | 740,205,550 |
Dividend Yield | 0% |
52-week-range | 11.24 - 29.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Todd Harris Ph.D. |
Website | https://www.tyra.bio |
An error occurred while fetching data.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD